Skip to main content
Premium Trial:

Request an Annual Quote

Omics-Driven Drug Discovery Firm Octant Raises $30M in Series A Financing Round

NEW YORK – Octant, a drug discovery firm seeking to use synthetic biology to find drug targets in complex biological networks, said on Wednesday that it has raised $30 million in Series A financing.

Silicon Valley venture capital firm Andreessen Horowitz led the round, joined by 8VC, SV Angel, Allen & Co, and several other undisclosed private investors.

"Our discovery platform was designed to map and measure the interconnected relationships between chemicals, multiple drug receptor pathways, and diseases, enabling us to engineer multi-targeted drugs in a more rational way, across a wide spectrum of targets," Octant CEO and Cofounder Sri Kosuri said in a statement. "By assaying massive numbers of drug receptor pathways at previously unthinkable scales, we are building what the biology is telling us the future of drug discovery will require."

Octant also announced that Swab-Seq, its RNA amplicon sequencing protocol, is freely available under the Open COVID Pledge license.

"By querying biology at this unprecedented scale, Octant has the potential to systematically create exhaustive maps of drug targets and corresponding, novel treatments for our most intractable diseases," Jorge Conde, general partner at Andreessen Horowitz and a member of the Octant board of directors, said in a statement.

Octant was cofounded by Kosuri, a professor of chemistry and biochemistry at the University of California, Los Angeles, and Ramsey Homsany, a tech executive with prior experience at Dropbox and Google. The firm's technology platform uses synthetic biology, genome engineering, next-generation sequencing, functional genomics, and computational tools to map the activity of thousands of receptor pathways in human cells, generating datasets and predictive insights that accelerate chemical discovery and optimization. Octant uses genetic barcodes to reveal chemical-receptor activity in a pooled fashion.

The firm aims to find small molecule, multi-target drug leads for multifactorial disease and is focusing its initial work on G-protein coupled receptor signaling networks. Octant is pursuing internal programs, as well as strategic partnerships with pharmaceutical partners.

The company's funding round is the latest investment from Andreessen Horowitz in companies with a genomics streak. The firm led health data firm Q Bio's $40 million Series B financing round earlier this year and participated in cancer blood testing firm Freenome's July 2019 $160 million Series B financing round.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.